Solventum Corp (SOLV) stock analysis
Solventum Corp (SOLV) clears 5 of this site's 8 mechanical value filters, 4 of 8 Buffett-style checks and 2 of 5 Lynch-style checks. At $87.45 it trades 395.3% above this site's neutral DCF value (a margin of safety of -395.3%). Its earnings quality rates Mixed and it returns −1.1% to shareholders net of dilution. Figures are as of October 23, 2026, from SEC filings and market data refreshed weekly; this is educational analysis, not investment advice.
Data as of October 23, 2026. Refreshed weekly from SEC filings and market data.
What does Solventum do?
Solventum makes medical, dental and infection prevention products, and health care software, spun off from 3M.
What stands out about Solventum?
- The share price implies more than 40% yearly growth. At $87.45, free cash flow per share would have to grow faster than 40% a year, fading to 2.5% by year 10, for this site's DCF to match the price. Change the assumptions.
- Misses 1 of the 8 value filters. It fails Market Cap > $25B ($14.9B); the other 5 pass and 2 were not evaluated. See every filter.
- Strongest against peers: P/E ratio. At 10.4× (peer median 24.6×) it ranks 2nd of 32 among health care stocks this site tracks. See the ranking.
- Weakest against peers: free-cash-flow yield. At 1.2% (peer median 5.5%) it ranks 34th of 34 among health care stocks this site tracks. See the ranking.
- Owners are being diluted. Its net shareholder yield is −1.1%: more stock is issued than is bought back or paid out. See Shareholder Yield Leaders.
How has Solventum's share price moved?
The interactive price chart needs JavaScript.
Is Solventum undervalued? The value diligence check
Every value-investing signal this site computes for this stock, gathered in one place: the same real numbers from the tools below, not a new score.
- Margin of safety (DCF) -395.3%
- P/E vs. its own history 10.4x · near the cheap end Real range: 8.9x–24.0x over 2 years (net income per diluted share from each fiscal year's 10-K, paired with the real closing price at that fiscal year-end).
- Wall St. analyst rating Buy · 3.82/5 22 analysts this month: 6 strong buy, 7 buy, 8 hold, 1 sell, 0 strong sell (Finnhub).
- Altman Z″-Score (bankruptcy risk) 2.34 · Grey zone
- Earnings quality (is the profit real?) Mixed · 2 watch Beneish M-score −2.08 (grey zone), mostly from profit running ahead of cash · accruals 8.3% of assets · 103% of profit arrived as cash · stock comp 1.9% of revenue · share count +0.7% a year. From the latest 10-K (year to Dec 2025) - see the Earnings Quality Screener for how each check is scored.
- Shareholder yield (cash back to owners) −1.1% net Latest fiscal year (2025): dividends 0.0% + buybacks 0.0% − stock comp 1.1%, as a share of today's market cap. Stock comp outruns what comes back in cash. See Shareholder Yield Leaders.
- Capital needed to grow (See's test) n/a (too few years of filings)
- PEG (growth at a reasonable price) 0.04 · Well under fair P/E 10.4× ÷ 271% a year of growth behind it. 4th lowest of 447 stocks with a usable PEG. Lynch's fair value is a PEG of 1; a very high PEG usually means almost no growth, a very low one a profit spike. See PEG Ratio Ranking.
- Compounder lenses (4) 2 of 4 · misses capital-light (n/a), cash back Capital-light growth: cannot be measured (too few years of filings); Profit is real: cleared; Cash to owners: not cleared (−0.7% a year net); Fair price (PEG): cleared. See Compounders at a Fair Price, which also lets you move the PEG bar.
- Value trap check Clear
- Munger's Inversion Check 1 flag
- Standing vs. sector peers 3 of 6 measures above the median Compared with the 33 other health care stocks this site tracks: 3 in the top third, 3 in the bottom third.
How does Solventum compare with its peers?
3 of 6 measures sit above the median of the 33 other health care stocks tracked here, 3 in the top third and 3 in the bottom third.
- P/E ratiolower is cheaper · peer median 24.6× 10.4× ✓2nd of 32
- Free-cash-flow yieldhigher is cheaper · peer median 5.5% 1.2% ✕34th of 34
- Return on equityhigher is better · peer median 15% 29% ✓8th of 34
- Net marginhigher is better · peer median 9.3% 17.3% ✓7th of 34
- Revenue growthhigher is better, year on year · peer median 8.6% −0.9% ✕33rd of 34
- Debt / equitylower is safer · peer median 0.69 1.10 ✕28th of 34
Peers are the stocks this site tracks in the same sector group, not every listed competitor. The bar runs from the weakest peer (left) to the strongest (right); the tick is the middle. Measures that don't apply to a sector (cash-flow yield for banks, debt for financials) are left out.
What would Buffett & Lynch say?
Buffett's checklist is built around durable, profitable businesses bought at sensible prices, and SOLV doesn't clear enough of it yet. In its favor: SOLV is currently earning a strong return on shareholders' equity, and has kept that profitability up over five years, not just this year, converts sales into profit at healthy margins, and earns many times its interest expense, so debt service isn't a worry. Where it comes up short: SOLV carries more debt relative to equity than he typically tolerates, hasn't grown earnings per share fast enough over five years to impress him, is trading above what a conservative discounted-cash-flow estimate says it's worth right now, and trades rich relative to owner earnings, the real cash the business could pay out.
- ROE (TTM) > 11% ✓
- ROE (5yr avg) > 11% ✓
- Debt/Equity < 0.5 ✕
- Pretax margin > 15% ✓
- EPS growth (5yr) > 7% ✕
- Interest coverage > 5x ✓
- Trading below intrinsic value (DCF) ✕
- Price vs. owner earnings < 25x ✕
Lynch looked for growth stories that weren't overpriced for that growth, and SOLV falls short of his bar. In its favor: SOLV clears an even tighter PEG-under-1 bar he'd want for a stock growing this fast, and isn't asking too much even by a fast grower's usual richer multiple. Where it comes up short: SOLV is growing earnings outside the 20-50% band he considered sustainable for a fast grower - either not fast enough to earn the label, or a pace he'd flag as unlikely to hold up, is leaning on more debt than he liked a growth story to carry, and isn't generating enough free cash flow to justify a fast grower's richer price.
- PEG < 1 (stricter for fast growers) ✓
- EPS growth 20%-50% ✕
- Debt/Equity < 0.5 ✕
- P/E < 40 ✓
- Price/FCF < 40 ✕
Quantitative approximations of each investor's documented approach, not endorsed by either investor or their estates - commentary, not this site's actual ranking criteria. Buffett never published a numeric checklist: only 2 of his 8 checks here trace to his own documented concepts ("owner earnings," from his 1986 shareholder letter, and "price is what you pay, value is what you get," his case against fixed P/E/P/B ceilings) - the other 6 (ROE, debt, margins, growth, interest coverage) use commonly-cited thresholds that are not numbers he himself published. The 8 hard filters below (plus the Munger check and Graham margin of safety) are this site's real, mechanical screen and are computed completely independently of the checklists above.
Berkshire Hathaway's own filing
Which of the 8 value filters does Solventum pass?
- Market Cap > $25B $14.9B
- Trailing P/E < 25 10.37
- PEG Ratio < 1.5 0.04
- Price/Book < 8 3.10
- Price/Sales < 7 1.79
- EPS Growth YoY > -5% +4.5%
- vs 50-day MA (±12%) Not evaluated †
- vs 200-day MA (±12%) Not evaluated †
What is Solventum's margin of safety?
History tracking starts this week - check back in a future week to see how this has moved.
Where is Solventum in its 52-week range?
What is the short interest in Solventum?
4,894,684 shares short as of 2026-09-30 (FINRA settlement date). Reported twice a month, so this only changes roughly every two weeks, not daily.
What could go wrong with Solventum? Munger's inversion check
"Invert, always invert." Instead of reasons to buy, these are reasons to hesitate, not a verdict, and not everything worth knowing about a business.
- Margin of safety, even in the bull case -193%
- Short interest under 5% of float 3.4%
- Passes most of the 6 fundamental filters 5/6 passed
- Price run-up backed by value, not just momentum +39% off 52wk low
- Debt/equity stable since 2023 0.00 → 1.00
Doesn't cover circle of competence, management quality, or accounting concerns: those need judgment, not data.
How much have Solventum shareholders gained per year?
Earnings growth per share plus dividend.
An earnings-based proxy, not a stock-price total return - it doesn't capture multiple expansion/contraction or reinvested dividends. EPS from SOLV's own 10-K filings; dividend yield is the current trailing yield on today's price, from the same weekly fetch as the rest of this site.
What do Solventum's 10-year financials show?
From SOLV's own 10-K filings (SEC EDGAR): up to the last 4 fiscal years. Press any year's bars for the exact figures.
Frequently asked questions about Solventum
What kind of company is Solventum?
Solventum makes medical, dental and infection prevention products, and health care software, spun off from 3M. This site groups it with Health Care stocks.
Is Solventum trading above or below its DCF value?
At $87.45, SOLV trades 395.3% above this site's neutral DCF value of $17.66 per share, a margin of safety of −395.3%. That DCF projects free cash flow for 10 years, with growth starting at 8% and fading to 2.5%, discounted at 10%; it is one set of assumptions, not a forecast. Test your own in the Intrinsic Value Calculator.
How many of this site's 8 value filters does Solventum pass?
SOLV passes 5 of 8. It passes Trailing P/E < 25 (10.37), PEG Ratio < 1.5 (0.04), Price/Book < 8 (3.10), Price/Sales < 7 (1.79) and EPS Growth YoY > -5% (+4.5%). It misses Market Cap > $25B ($14.9B). vs 50-day MA (±12%) and vs 200-day MA (±12%) were not evaluated, because the moving-average checks only run on stocks that clear the fundamentals first. The 8-filter list shows every stock that passes all of them.
Are Solventum's reported earnings reliable?
This site's earnings-quality check rates SOLV Mixed · 2 watch. Beneish M-score −2.08 (grey zone), mostly from profit running ahead of cash · accruals 8.3% of assets · 103% of profit arrived as cash · stock comp 1.9% of revenue · share count +0.7% a year. From the latest 10-K (year to Dec 2025). Concerns: the Beneish M-score (on watch) and accruals (on watch). The five checks are the Beneish M-score (manipulation risk), accruals, cash conversion, stock-based compensation and share dilution; the Earnings Quality Screener shows how each is graded.
How risky is Solventum's balance sheet?
SOLV's Altman Z″-Score is 2.34, which falls in the grey zone. Altman's own thresholds are above 2.6 for the safe zone, 1.1 to 2.6 for the grey zone and below 1.1 for the distress zone; the score blends working capital, retained earnings, operating profit and equity against liabilities. Its debt-to-equity ratio is 1.10. See the Altman Z″-Score list.
When does Solventum report earnings next?
Solventum's next earnings report is expected on November 5, 2026, with analysts expecting earnings of $1.38 per share. Dates come from the Finnhub earnings calendar and can move. In its last 4 quarters it beat the estimate 4 times, by an average of +11.0%.
Where do these numbers come from?
- Financial statements: Solventum's 10-K annual report for the year ended Dec 31, 2025, filed Feb 27, 2026 (filing index). Every earlier year in the 10-year financials comes from the company's older 10-K filings, all listed on SEC EDGAR.
- Prices and market data: quotes, P/E and analyst ratings from Finnhub; daily price history and the 52-week range from Twelve Data, both refreshed weekly. Short interest comes from FINRA, reported twice a month.
- How to check a figure: click any number in the card above to see its exact source, and read the Editorial Standards for every rule behind the checks.
About this Solventum Corp analysis
This page shows every value-investing check the site runs on Solventum Corp (SOLV) in one place: the 8 mechanical filters, the Buffett and Lynch checklists, a margin of safety from a disclosed DCF, earnings quality, shareholder yield and how it ranks against its sector peers. The numbers come from SEC filings and public market data, refreshed weekly, and the same rules apply to every stock on the stock list. See Editorial Standards for the sources and the rules, or run your own filters in the stock screener.